Ocugen annual ebitda
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Ocugen EBITDA Growth & History (OCGN)
Ocugen's calculated EBITDA was −$60.5M for fiscal 2025.
View full Ocugen company overviewOcugen annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$60.5M | −$7.7M | — |
| 2024 | 2024-12-31 | −$52.9M | $12.0M | — |
| 2023 | 2023-12-31 | −$64.8M | $23.8M | — |
| 2022 | 2022-12-31 | −$88.6M | −$30.8M | — |
| 2021 | 2021-12-31 | −$57.8M | −$36.6M | — |
| 2020 | 2020-12-31 | −$21.2M | −$7.1M | — |
| 2019 | 2019-12-31 | −$14.1M | $2.0M | — |
| 2018 | 2018-12-31 | −$16.1M | $7.3M | — |
| 2017 | 2017-12-31 | −$23.4M | $5.2M | — |
| 2016 | 2016-12-31 | −$28.6M | $1.6M | — |
| 2015 | 2015-12-31 | −$30.2M | $1.7M | — |
| 2014 | 2014-12-31 | −$31.9M | — | — |
Ocugen quarterly ebitda
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$15.8M | −$2.6M | — |
| Q1 2026 | 2026-03-31 | −$17.2M | −$3.3M | — |
| Q4 2025 | 2025-12-31 | −$16.4M | — | — |
| Q3 2025 | 2025-09-30 | −$17.8M | — | — |
| Q2 2025 | 2025-06-30 | −$13.2M | — | — |
| Q1 2025 | 2025-03-31 | −$13.9M | — | — |
| Q4 2021 | 2021-12-31 | −$14.5M | −$10.8M | — |
| Q3 2021 | 2021-09-30 | −$10.7M | −$526,800 | — |
| Q2 2021 | 2021-06-30 | −$25.6M | −$22.2M | — |
| Q1 2021 | 2021-03-31 | −$7.0M | −$3.1M | — |
| Q4 2020 | 2020-12-31 | −$3.8M | $451,640 | — |
| Q3 2020 | 2020-09-30 | −$10.2M | −$7.5M | — |
| Q2 2020 | 2020-06-30 | −$3.3M | −$1.0M | — |
| Q1 2020 | 2020-03-31 | −$3.9M | $915,438 | — |
| Q4 2019 | 2019-12-31 | −$4.2M | −$3.4M | — |
| Q3 2019 | 2019-09-30 | −$2.7M | −$390,802 | — |
| Q2 2019 | 2019-06-30 | −$2.3M | $4.8M | — |
| Q1 2019 | 2019-03-31 | −$4.8M | $1.1M | — |
| Q4 2018 | 2018-12-31 | −$781,434 | $4.9M | — |
| Q3 2018 | 2018-09-30 | −$2.3M | $3.0M | — |
| Q2 2018 | 2018-06-30 | −$7.1M | −$1.1M | — |
| Q1 2018 | 2018-03-31 | −$5.9M | $515,000 | — |
| Q4 2017 | 2017-12-31 | −$5.7M | $1.8M | — |
| Q3 2017 | 2017-09-30 | −$5.3M | $931,000 | — |
| Q2 2017 | 2017-06-30 | −$6.0M | $1.5M | — |
| Q1 2017 | 2017-03-31 | −$6.4M | $932,000 | — |
| Q4 2016 | 2016-12-31 | −$7.5M | $383,000 | — |
| Q3 2016 | 2016-09-30 | −$6.2M | $1.4M | — |
| Q2 2016 | 2016-06-30 | −$7.5M | −$327,000 | — |
| Q1 2016 | 2016-03-31 | −$7.4M | $134,000 | — |
| Q4 2015 | 2015-12-31 | −$7.9M | −$1.6M | — |
| Q3 2015 | 2015-09-30 | −$7.6M | $7.1M | — |
| Q2 2015 | 2015-06-30 | −$7.2M | −$1.3M | — |
| Q1 2015 | 2015-03-31 | −$7.5M | −$2.5M | — |
| Q4 2014 | 2014-12-31 | −$6.3M | — | — |
| Q3 2014 | 2014-09-30 | −$14.8M | — | — |
| Q2 2014 | 2014-06-30 | −$5.8M | — | — |
| Q1 2014 | 2014-03-31 | −$5.0M | — | — |
Ocugen ebitda trends
Over the last five fiscal years, Ocugen's ebitda decreased from −$21.2M to −$60.5M, a change of −$39.3M. The latest reported quarter, Q2 2026, shows −$15.8M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ocugen source filings ↗Community posts
Ocugen receives provisional Bahamas clearance for OCU400 access pathway
Ocugen ($OCGN) received provisional approval and priority designation from the Bahamas’ Longevity and Regenerative Therapies Board for OCU400, its experimental gene therapy for retinitis pigmentosa. The company intends to supply the treatme ...
